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Abstract
Background: The dysbiosis of intestinal microbiota plays an important role in the development of gut-derived
infections, making it a potential therapeutic target against multiple organ dysfunction syndrome (MODS) after
sepsis. However, the effectiveness of fecal microbiota transplantation (FMT) in treating this disease has been rarely
investigated.
Methods: Two male patients, a 65-year-old and an 84-year-old, were initially diagnosed with cerebellar hemorrhage
and cerebral infarction, respectively, after admission. During the course of hospitalization, both patients developed
MODS, septic shock, and severe watery diarrhea. Demographic and clinical data were collected. Intestinal dysbiosis
was confirmed by 16S rDNA-based molecular analysis of microbiota composition in fecal samples from the two
patients. The two patients each received a single nasogastric infusion of sterile-filtered, pathogen-free feces from
a healthy donor. Fecal samples were collected every two days post infusion to monitor changes in microbiota
composition in response to treatment.
Results: Following FMT, MODS and severe diarrhea were alleviated in both patients. Their stool output and body
temperature markedly declined and normalized. Significant modification of microbiota composition, characterized
by a profound increase of commensals in the Firmicutes phylum and depletion of opportunistic organisms in
the Proteobacteria phylum, was observed in both patients. Furthermore, we identified a reconstituted bacterial
community enriched in Firmicutes and depleted of Proteobacteria that was associated with a decrease in the
patients’ fecal output and in the levels of plasma inflammation markers.
Conclusions: The outcome of treating two patients with FMT indicates that restoration of the intestinal microbiota
barrier can alleviate the infection and modulate the immune response. These findings warrant further investigation
of FMT as a putative new therapy for treating microbiota-related diseases such as MODS.
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Background
The normal function of the gastrointestinal tract is im-
portant for immune defense against pathogens in the
human body. It is now well-acknowledged that gut
microbiota may serve as a physical barrier that maintains
mucosal integrity by preventing penetration of the epi-
thelial barrier by pathogens and by modulating immuno-
logical activity [1]. Disruption of the gut microbiota
barrier contributes to the development of many gastro-
intestinal diseases along with multiple extraintestinal
diseases [2]. Fecal microbiota transplantation (FMT) has
been proposed as a treatment for restoring the gut
microbiota barrier [3, 4]. Recently, it has been shown
that FMT can cure recurrent Clostridium difficile infec-
tion (CDI), which results from persistent disruption of
commensal gut microbiota, by reestablishing the intes-
tinal microbiota balance [5]. However, the nature of this
restoration and whether a transition to an ecologically
stable intestinal microbial population takes place during
FMT treatment remains to be elucidated.
Multiple organ dysfunction syndrome (MODS), which
in most cases occurs secondary to severe sepsis or septic
shock, trauma, neoplastic diseases, and other causes of
systemic inflammatory response syndrome (SIRS), refers
to the presence of impaired function in multiple organs
so that homeostasis cannot be maintained without med-
ical intervention [6]. The pathophysiology of MODS is
complex, multifactorial, and poorly understood. Emer-
ging evidence suggests that translocation of microbes or
components of microbes from the gastrointestinal tract
and immune system dysregulation might be involved [7].
Thus, FMT might play a therapeutic role in the manage-
ment of MODS following severe sepsis. The efficacy of
FMT in treating recurrent CDI further encouraged us to
investigate the value of this therapeutic approach in pa-
tients with MODS after sepsis. In this article, we de-
scribe two cases of patients who developed MODS and
severe diarrhea following severe sepsis and report their
outcomes following treatment with FMT. We also inves-
tigated the changes in composition and abundance of in-
testinal bacteria in these patients with MODS in
response to FMT and characterized the relationship be-
tween these FMT-induced alterations in gut microbiota
and immunological marker profiles.
Case presentation
Case 1: a 65-year-old male patient with sudden loss of
consciousness and an initial diagnosis of encephalorrha-
gia was transferred to our hospital from another medical
facility. Cerebral computed tomography (CT) confirmed
the diagnosis of cerebellar hemorrhage. This patient was
then admitted to the Department of Neurosurgery, and
the cerebellar hematoma was surgically removed via the
posterior middle approach. After surgery, the patient
was in a persistent light coma, but defecation was nor-
mal. At 6 days post surgery, the patient was passing yel-
low pasty stool once a day, but this frequency later
increased to 3–4 times a day.
On postoperative day 8, the patient developed pul-
monary infection and progressed to acute respiratory
distress syndrome (ARDS), then suffered type I respira-
tory failure. This patient went into a coma after the op-
eration and had intermittent irritability and much airway
mucus; therefore, it was considered that the pulmonary
infection was more severe. Thus, in order to aspirate the
sputum and maintain airway patency, we carried out a
tracheotomy. The patient was admitted to the intensive
care unit (ICU) with a diagnosis of septic shock and
MODS. The acute physiology and chronic health evalu-
ation (APACHE) II score was 23, and the white blood
cell (WBC) count increased to 26.22 × 109/L with 84.2 %
neutrophils. His blood cultures now yielded Acinetobac-
ter baumannii. The patient had a persistently high fever,
with a peak temperature of 39.6 °C, despite administra-
tion of antibacterial and antifungal therapy. Meanwhile,
the sputum culture showed mycotic infection, so oral
itraconazole was added. However, the patient’s condition
continued to worsen.
On the 20th day of hospitalization, the patient devel-
oped septic shock. Antibiotics were changed to imipe-
nem/cilastatin and vancomycin, while itraconazole was
continued. The patient then had progressive diarrhea on
average 6–12 times a day, with a total volume of 1000–
2200 mL per day, with stool of a pasty jam consistency.
We carried out comprehensive bacteriological investiga-
tions, including stool bacterial culture and fungal cul-
ture, and tested for Clostridium difficile toxin A and B.
All results were negative. The fecal bacteria population
was analyzed, and the results indicated severely per-
turbed intestinal microflora. Based on the above find-
ings, this patient was rendered a good candidate for
treatment with FMT. Therefore, FMT was performed
once, and the anti-infection therapy was stopped.
Case 2: an 84-year-old male patient with right-sided
weakness and fever was admitted. CT confirmed the
presence of cerebral infarction near the left lateral ven-
tricle and pulmonary infection. The patient was then
transferred to ICU due to infection-induced respiratory
failure. His blood cultures now yielded Burkholderia
cepacia. Antibiotics were changed from imipenem/cilas-
tatin to cefoperazone/sulbactam. On the fourth day of
hospitalization, fluconazol was added due to the discov-
ery of pseudohyphae in the sputum. The pneumonia im-
proved, but the patient suffered from fever and diarrhea
after the use of multiple antibiotics. The anti-infection
therapy was ineffective. In addition, metronidazole, pro-
biotics, and loperamide were useless in treating the diar-
rhea. Consequently, the patient’s fever persisted, and he
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progressed to MODS. His APACHE II score was 20.
Continuous hemofiltration was given for aggravated
renal failure on the seventh day of hospitalization. The
patient had diarrhea 4–8 times a day, with a total stool
volume of 1000–2000 mL per day. We carried out com-
prehensive bacteriological investigations for this patient
too, including stool bacterial culture and fungal culture,
and tested for C. difficile toxin A and B. All results were
negative. As was the case for the first patient, analysis of
the fecal bacteria indicated severe microflora imbalance
and thus, a likelihood of successful treatment with FMT.
Based on the experience of treating the first patient, the
same FMT regimen was administered to this patient.
Methods
Analysis of fecal microbiota
To confirm our suspicion of intestinal dysbiosis, we
used 16S rRNA gene-based molecular techniques to
characterize the fecal bacterial composition in our two
patients according to the following procedure [8]. DNA
was extracted from fecal samples, stored at −80 °C, and
later purified by standard methods. DNA density and
quality were evaluated using the NanoDrop spectropho-
tometer (ThermoFisher Scientific-NanoDrop Products,
Wilmington, DE, USA), Qubit fluorometer (Thermo-
Fisher Scientific-Life Technologies, Grand Island, NY,
USA), and agarose gel electrophoresis. Extracted DNA
was diluted to 2 ng/μL and stored at −20 °C until se-
quencing of 16S gene amplicons.
Universal primers (5′-GTACTCCTACGGGAGGCAG
CA-3′ and 5′-GTGGACTACHVGGGTWTCTAAT-3′)
with 8 nt index barcodes were used to amplify the V3V4
hypervariable regions of 16S rRNA genes for subsequent
sequencing using the MiSeq sequencer (Illumina, San
Diego, CA, USA) [9, 10]. The PCR mixture (25 μL) con-
tained 1 × PCR buffer, 1.5 mM MgCl2, 0.4 μM of each
deoxynucleoside triphosphate, 1.0 μM of each primer, 1
U of TransStart FastPfu DNA Polymerase (TransGen,
Beijing, China), and 4 ng genomic DNA. The PCR amp-
lification program included initial denaturation at 94 °C
for 3 minutes; followed by 23 cycles of 94 °C for 30 s,
60 °C for 40 s, and 72 °C for 60 s; and final extension at
72 °C for 10 minutes. PCR products were visualized in
triplicate by electrophoresis on 1.0 % agarose gels and
then compared to a DNA ladder to identify the bands of
correct size. These bands were then excised and purified
using the EZNA Gel Extraction Kit (Omega Bio-tek,
Norcross, GA, USA) and quantified with the Qubit
fluorometer. All replicates of each sample, in equal
molar amounts, were pooled.
The sequencing library was prepared using the TruSeq
DNA Kit (Illumina) according to manufacturer’s instruc-
tions. In accordance with the Illumina library prepar-
ation protocols, purified DNA was diluted, denatured,
rediluted, and mixed with PhiX (equal to 30 % of the
final DNA amount). The library was then sequenced
with Reagent Kit v3 for 600 cycles in the MiSeq system,
as described in the manufacturer’s manual. Using the
Quantitative Insights into Microbial Ecology (QIIME)
pipeline [11], the raw sequences were processed to con-
catenate reads into tags according to the overlapping re-
lationship, then reads belonging to each sample were
separated with barcodes and low quality reads were re-
moved. The processed tags were clustered, and the oper-
ational taxonomic units (OTUs) were assigned to taxa
by matching to the Greengenes database [12].
FMT procedure
On analysis the fecal microbiota from the two patients
were extensively perturbed (Fig. 2, day (d) 0) and
therefore, we were very interested in trying to manage
their microbiota disorders using FMT. The infusion of
donor feces was performed in the two patients on day 0
(Figs. 1, 2, 3 and 4). The patients were each given FMT
once. A graduate student (27 years old) was selected as
the donor of fecal microbiota. He screened negative for
blood-borne communicable diseases, and his fecal
samples tested negative for common stool pathogens
such as HAV-IgM, HBsAg, HCV-IgG, HDV-Ab, HEV-
IgM, HIV, CMV, syphilis, roundworm, pinworm, hook-
worm, amoeba and duovirus, and so on. Fresh stool
(150 g) collected on the day of infusion was diluted with
350 mL sterile saline. The homogenized solution was
filtered twice through a pre-sterilized metal sieve. The
filtrates (250 mL) were infused into each patient via a
nasogastric tube. Each patient’s stool was collected every
5 days, and a 220-mg aliquot of each sample was
immediately frozen at −80 °C until DNA extraction. We
carried out 16 s RNA bacterial floral analysis of stool
samples that were obtained by means of one stool
sample every 5 days from each patient and the donor,
and the methods and steps were the same as those de-
scribed above.
Serum inflammatory marker assays
Serum IL-6 was measured using enzyme-linked im-
munosorbent assay kits (R&D Systems, Abingdon, UK).
The blood samples were collected and sent to the
Department of Laboratory Testing in Daping Hospital
for the detection of procalcitonin (PCT), C-reactive pro-
tein (CRP), and erythrocyte sedimentation rate (ESR).
CRP (mg/L) was measured in capillary blood using the
device QuikRead go CRP +Hb (Orion Diagnostica, Oy,
Finland), which works on the principle of photometry
and turbidimetry. ESR was measured using the Coulter
GenS System (Coulter, Miami, FL, USA). PCT was
measured using the immunochromatographic assay
(Guangzhou Wondfo Biotech Co., Ltd. China).
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Statistical analysis
Correlation between two variables was tested by linear
regression analysis with the Pearson test. The relative in-
tensity of each band was calculated and expressed as a
percentage of the sum of all fragments in the same lane
of the gel. We also conducted OTU and principal com-
ponent (PC) analyses with CANOCO software 4.5 for
Windows (Microcomputer Power, Ithaca, NY, USA). A
P value <0.05 was considered statistically significant.
Results
Changes in intestinal microflora following FMT
The proportion of nonpathogenic microbiota in the
healthy donor feces (i.e., Streptococcus, Bacillus coli,
Streptococcus thermophilus, Bacillus acidi lactici,
Lactobacillus plantarum) was greater than that of the
pathogenic bacteria (i.e., Enterobacter cloacae, Yersinia
enterocolitica, Klebsiella pneumoniae). Consistent with
the data obtained from the molecular phylogenetic tree,
the OUT and PC analyses (Fig. 1a and b) both showed
that the structure of the microbiome was dramatically
changed in both patients compared to that of the donor.
However, the gut microbiota structure in the patients
showed a profound trend toward that of the donor feces,
especially at 20 days post FMT in patient 1 and at
10 days post FMT in patient 2. The distance between
the points representing the donor’s and patient’s micro-
biota decreased from 0.925 to 0.296 and from 0.637 to
0.289 in patient 1 and patient 2, respectively.
Compared to day 0, significant growth of bacteria in
the Firmicutes phylum was noted at 20 days post FMT
in both patients (Fig. 2a). In patient 1, the percentage of
Actinobacteria was substantially decreased and became
approximately equal to that of the healthy donor at
20 days post FMT. Bacteria in the Bacteroidetes and Fir-
micutes phyla increased and became approximately
equal to that of the healthy donor at 15 days post FMT.
There was an increasing trend for expression of Proteo-
bacteria phylum genes by 5 days after FMT, and then it
slowly decreased. Finally, it was probably stabilized at a
level basically equivalent to that of the donor at 15 days
after FMT. In patient 2, the populations of Bacteroidetes
Fig. 1 Changes in the gut microbiota of patients under fecal microbiota transplantation (FMT) treatment. a Clustering tree of weighted unifrac
distances of microbial composition among different sampling time points. After receiving FMT, over time the gut microbiota of the two patients
tended to approximate that of the donor. b Principal coordinate analysis (PCA) of the genus profile. The top four genera as the main contributors
were determined and plotted by their loadings in these two components. d day
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Fig. 2 Predominant fecal microbiota composition in the donor and patients (case 1 and case 2) at the phyla level (a), the class level (b), the order
level (c), the family level (d), and the genus level (e). Variations in the microbiota composition are shown at the representative time points in the
days (d) following fecal microbiota transplantation
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Fig. 3 Volume of stool output in the two patients at time points (days) before and after fecal microbiota transplantation (Day 0)
Fig. 4 Serum levels of IL-6 (a), C-reactive protein (CRP) (b), procalcitonin (PCT) (c) and erythrocyte sedimentation rate (ESR) (d) in the two patients
(case 1 and case 2) before and after fecal microbiota transplantation (DAY 0)
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and Proteobacteria decreased to levels similar to those
of a healthy donor by 10 days and 15 days post FMT, re-
spectively (Fig. 2a).
Changes in the proportions of fecal microbiota at the
class and order level were observed in both patients, and
these altered proportions tended to follow those of the
donor (Fig. 2b and c). The families Ruminococcaceae,
Lachnospiraceae, and Veillonellaceae were significantly
increased in patient 1 and contributed mostly to the
boom of Firmicutes, while families Ruminococcaceae,
unclassified Clostridiales, and Lachnospiraceae increased
in patient 2 (Fig. 2d). The Proteobacteria families, En-
terobacteriaceae and Alcaligenaceae, were significantly
decreased in patient 1, while Enterobacteriaceae was sig-
nificantly decreased in patient 2 (Fig. 2d). At the genus
level (Fig. 2e), Roseburia, Prevotella, Dialister, Faecali-
bacterium, Bacteroides, and Oscillospira were increased
in patient 1, with a rapid reduction of Sutterella. In pa-
tient 2, Blautia and Roseburia were increased after FMT,
and Bacteroides was significantly decreased.
Clinical outcomes
On the basis of the evidence of disturbed microbiota in
the two patients, we applied FMT for the treatment of
MODS and severe diarrhea, after conventional strategies
with antibiotics and probiotics had failed. The patients’
septic symptoms and diarrhea were expected to improve
after FMT. At day 1 post FMT, patient 1 had a decrease
in body temperature from 39.6 °C prior to the infusion
to 37.1 °C after infusion, and patient 2 had a decrease in
body temperature from 38.3 °C to 37.3 °C. In the follow-
ing days post FMT, neither patient had recurrence of
MODS symptoms, and blood cultures from both pa-
tients remained sterile. Stool output from both patients
declined after 7 days (Fig. 3), and their stools became
well-formed. In patient 1, the fecal consistency became
normal at 6 days post FMT. Stool frequency and volume
returned to normal at 14 and 16 days post FMT in pa-
tient 1 and patient 2, respectively.
In addition, the serum levels of CRP, ESR, PCT and
IL-6 in both patients were significantly decreased at day
20 post FMT, compared to those at day 0 (patient 1:
CRP 88.3 vs. 1.0 mg/L, ESR 39 vs. 7 mm/h, PCT 0.79 vs.
0.18 μg/L, IL-6 216.9 vs. 6.7 pg/mL; patient 2: CRP 66.3
vs. 7.0 mg/L, ESR 26 vs. 11 mm/h, PCT 0.45 vs. 0.07 μg/
L, IL-6 193.6 vs. 9.7 pg/mL). (Fig. 4). The level of con-
sciousness in patient 1 improved, and he had normal
respiration at 19 days post FMT. Patient 2 had a full re-
covery and was discharged from hospital.
Discussion
The incidence of gastrointestinal infection, which results
from MODS but also aggravates the disease, is relatively
high in MODS patients, and gut microbiota imbalance
may contribute to the infection [13]. Thus, FMT, which
can help reconstruct the impaired gut microbiota barrier
and correct the dysbiosis in patients in the ICU, has
therapeutic potential for treating MODS [14, 15]. In this
paper, we have reported two patients with sepsis,
MODS, and severe diarrhea who were successfully
treated by transplantation of fecal microbiota from a
healthy donor. Our results are consistent with a previous
case report of one patient with severe sepsis and diar-
rhea following vagotomy, who was successfully treated
by FMT [16].
Recent studies have shown that the gut is the depot
for bacteria and endotoxins associated with SIRS and
MODS [7]. All elements of the gut - the epithelium, the
immune system, and the microbiome - are impacted by
critical illness, and can in turn propagate a pathologic
host response [17]. Prior to FMT, the most notable
changes in the fecal microbiota of patient 1 were in-
creased Actinobacteria and decreased Firmicutes and
Proteobacteria, and the most notable changes in the
fecal microbiota of patient 2 were increased Bacterio-
detes and Proteobacteria and decreased Firmicutes,
compared with the fecal microbiota of the healthy
donor. Because it makes up the largest part of the hu-
man gut microbiome and contains the genus Lactobacil-
lus [18], the Firmicutes phylum could be beneficial to
the normal function of the gastrointestinal tract. It is
known that pathogenic bacteria translocate and prolifer-
ate more than the nonpathogenic ones, which can lead
to gut barrier disruption, infection, and ultimately SIRS
and MODS, by releasing multiple cytokines. The
changes in microbiota composition observed in our pa-
tients could help further our understanding of the im-
portance of maintaining a normal gut microbiota barrier
and the feasibility of treating patients by restoring it.
Although FMT has been proposed as an effective
method for correcting the dysbiosis among patients in
the ICU and for restoring the normal gut microflora, its
therapeutic role has not been completely explored [19,
20]. In our patients, the infection and diarrhea were alle-
viated by FMT, and the systemic immune response was
also attenuated. The stool volume and frequency had in-
creased significantly before FMT in both patients, but
were gradually reduced after FMT. The stool was grad-
ually formed. Here, we need to explain that at 3 days be-
fore FMT, we stopped all treatment with antibiotics in
both of the patients so that the patients entered into an
antibiotic washout period to prepare for later FMT. Be-
cause no antibiotics were present to further destroy the
intestinal flora in this time range, the intestinal flora
might recover somewhat. Therefore, the amounts of
stool in the two patients fluctuated at 5 days before
FMT. Sometimes the amounts were increased, some-
times they were decreased, and the overall trend was
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towards a decrease, but the stool frequencies in the two
patients were still very high before FMT. In addition,
there was no trend towards well-formed stool, and the
overall composition of the stool was still similar to that
of diarrhea. After being treated with FMT, the amounts
of stool in the two patients were rapidly decreased, the
stool frequencies were significantly decreased, and the
stool gradually became well-formed. These findings indi-
cate that the significant improvement in symptoms of
diarrhea in the patients still depends on recovery of the
balance of the intestinal flora due to FMT.
We observed decreased levels of IL-6, CRP, PCT, and
ESR in both patients following FMT. An interesting
phenomenon was seen in that although there was a
trend towards a decrease in the overall levels of inflam-
matory factors such as IL-6 and CRP, the levels fluctu-
ated somewhat in the first few days. A similar pattern
was observed for PCT and ESR. However, all of these
were minor changes. We hypothesize that these changes
may be correlated with restoration of the intestinal flora
and the improvement in clinical symptoms to some
extent in patients after we stopped using antibiotics
before FMT. The trend towards a decrease in these
inflammatory factors also indicates that FMT might
play an important role in the regulation of the im-
mune system [21].
In an effort to identify a possible mechanism under-
lying the clinical benefits achieved in our patients, we
evaluated the temporal changes in the microbiota com-
position following FMT. We further identified the varia-
tions in the composition of the microbiota in our
patients following FMT under different OTU annotation
levels. By comparing the fecal microbiota before and
after FMT, we observed a transition to normal quantities
(patient 1) or to a normal distribution (patient 2) of the
aforementioned bacterial phyla found to be imbalanced
(when compared with those in the healthy donor) before
FMT, which is of valuable clinical significance. Changes
in the proportions of fecal microbiota at the class, order,
family, and genus levels were also observed in both pa-
tients following FMT, and these altered proportions
tended to approach those of the donor. These findings
suggest that reshaping the gut microbiota might be the
fundamental mechanism of FMT in treating sepsis-
associated MODS and that FMT is capable of restoring
the normal quantities and/or the normal distribution of
intestinal microbiota in patients with MODS.
Conclusion
The main limitation of our study is that only two pa-
tients were included in our cohort, and thus it can serve
only as a pilot investigation of the clinical application of
FMT. We believe that our findings warrant future re-
search with a larger cohort of patients to further explore
the underlying mechanisms of the therapeutic effects of
FMT and to define the appropriate conditions for its
use. In conclusion, our results demonstrate the clinical
effectiveness of FMT in treating patients with sepsis-
associated MODS and diarrhea. FMT is capable of sig-
nificantly alleviating septic complications by restoring
the normal quantity and/or distribution of beneficial gut
microbiota and correcting the dysbiosis among patients
in the ICU. Thus, FMT shows promise as a putative
novel therapy for MODS and diarrhea following severe
sepsis.
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